• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates.

作者信息

Harrison A, Walker C A, Parker D, Jankowski K J, Cox J P, Craig A S, Sansom J M, Beeley N R, Boyce R A, Chaplin L

机构信息

MRC Radiobiology Unit, Chilton, Didcot, Oxon, England.

出版信息

Int J Rad Appl Instrum B. 1991;18(5):469-76. doi: 10.1016/0883-2897(91)90107-v.

DOI:10.1016/0883-2897(91)90107-v
PMID:1917516
Abstract

Yttrium binding ligands DOTA, caDTPA and CT-DTPA were each conjugated to monoclonal antibody B72.3, labelled with 90Y and injected into mice in order to assess the in vivo inertness of the antibody-linked 90Y-ligand complexes. Levels of 90Y in femur shafts of the DOTA-B72.3 mice were low, being approximately 7 and 44%, respectively, of levels in the femur shafts of the caDTPA-B72.3 and CT-DTPA-B72.3 treated mice. This finding demonstrates the greater inertness and by implication the greater suitability for immunotherapy of the DOTA-90Y complex.

摘要

相似文献

1
The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates.
Int J Rad Appl Instrum B. 1991;18(5):469-76. doi: 10.1016/0883-2897(91)90107-v.
2
Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.111铟和90钇标记的与嵌合抗癌胚抗原抗体偶联的DOTA及马来酰亚胺基半胱氨酸酰胺基-DOTA在荷瘤裸鼠体内的生物分布：稳定和化学不稳定连接体系统的比较
Bioconjug Chem. 1998 Jan-Feb;9(1):87-93. doi: 10.1021/bc970137n.
3
Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.CHX-DTPA及其他用于单克隆抗体钇标记的配体的血清稳定性和体内生物分布评估。
J Nucl Med. 1994 May;35(5):882-9.
4
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.90Y-多胺基多羧基大环配体-人源化抗CD19单克隆抗体：一种用于非霍奇金淋巴瘤放射免疫治疗的药物。
J Nucl Med. 2003 Jan;44(1):77-84.
5
Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3.与B72.3偶联的111铟、177镥和90钇标记的DOTA类似物的制备及生物学评价
Nucl Med Biol. 2007 Jul;34(5):493-502. doi: 10.1016/j.nucmedbio.2007.03.006. Epub 2007 Jun 8.
6
Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.钇-90生物素三步放射免疫疗法：癌症患者的剂量测定与药代动力学
Eur J Nucl Med. 1999 Feb;26(2):110-20. doi: 10.1007/s002590050366.
7
Biodistribution in tumour-bearing mice of two 90Y-labelled biotins using three-step tumour targeting.使用三步肿瘤靶向法在荷瘤小鼠体内对两种90Y标记生物素的生物分布情况。
Nucl Med Commun. 1997 Feb;18(2):176-82. doi: 10.1097/00006231-199702000-00014.
8
Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.预靶向单克隆抗体2D12.5和88Y-双功能螯合剂-2-(对硝基苄基)-1,4,7,10-四氮杂环十二烷四乙酸（DOTA）在携带KHJJ小鼠腺癌的BALB/c小鼠体内的药代动力学：一种90Y放射免疫治疗模型
Cancer Res. 1994 Nov 15;54(22):5937-46.
9
90Y.B72.3 against pancreatic cancer: dosimetric and biological analysis.90Y标记的B72.3针对胰腺癌的剂量学和生物学分析。
Int J Radiat Oncol Biol Phys. 1990 Sep;19(3):627-31. doi: 10.1016/0360-3016(90)90489-7.
10
A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.一种用DOTA修饰蛋白质的简便、水溶性方法。利用高温和优化的pH值在放射性标记免疫缀合物中实现高比活性和高螯合物稳定性。
Bioconjug Chem. 1994 Nov-Dec;5(6):565-76. doi: 10.1021/bc00030a012.

引用本文的文献

1
Force Fields, Quantum-Mechanical- and Molecular-Dynamics-Based Descriptors of Radiometal-Chelator Complexes.基于力场、量子力学和分子动力学的放射性金属螯合物配合物描述符。
Molecules. 2024 Sep 17;29(18):4416. doi: 10.3390/molecules29184416.
2
Radiolabeled F(ab')-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models.放射性标记的 F(ab')-西妥昔单抗用于结直肠和皮肤肿瘤荷瘤小鼠模型的诊断和治疗。
Clin Transl Oncol. 2018 Dec;20(12):1557-1570. doi: 10.1007/s12094-018-1886-4. Epub 2018 May 17.
3
A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.
螯合剂H4octapa和CHX-A″-DTPA与治疗性放射性金属（90）Y的对比评估。
Nucl Med Biol. 2016 Sep;43(9):566-576. doi: 10.1016/j.nucmedbio.2016.06.004. Epub 2016 Jun 28.
4
Impairment of lymphocyte function following yttrium-90 DOTATOC therapy.钇-90 DOTATOC治疗后淋巴细胞功能受损。
Cancer Immunol Immunother. 2015 Jun;64(6):755-64. doi: 10.1007/s00262-015-1687-3. Epub 2015 Mar 31.
5
Synthesis and evaluation of a new bifunctional NETA chelate for molecular targeted radiotherapy using(90)Y or(177)Lu.一种用于使用（90）钇或（177）镥进行分子靶向放射治疗的新型双功能NETA螯合物的合成与评估。
Nucl Med Biol. 2015 Mar;42(3):242-9. doi: 10.1016/j.nucmedbio.2014.10.004. Epub 2014 Oct 20.
6
H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu.H6phospa-trastuzumab：一种基于亚甲基膦酸的双功能螯合剂，可与 89Zr、111In 和 177Lu 结合。
Dalton Trans. 2014 Jan 7;43(1):119-31. doi: 10.1039/c3dt51940f.
7
H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy.H(4)八聚体曲妥珠单抗：用于铟-111和镥-177成像及治疗的多功能非环状螯合体系
J Am Chem Soc. 2013 Aug 28;135(34):12707-21. doi: 10.1021/ja4049493. Epub 2013 Aug 15.
8
Convenient Synthesis and Evaluation of Heptadentate Bifunctional Ligand for Radioimmunotherapy Applications.用于放射免疫治疗的七齿双功能配体的简便合成与评估
European J Org Chem. 2011 Nov 1;2011(33):6641-6648. doi: 10.1002/ejoc.201101063.
9
Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy.双功能配体的合成及临床前评价：提高 90Y 和 177Lu 的螯合化学性能，用于靶向放射免疫治疗。
Bioconjug Chem. 2012 Sep 19;23(9):1775-82. doi: 10.1021/bc200696b. Epub 2012 Aug 10.
10
86Y based PET radiopharmaceuticals: radiochemistry and biological applications.基于 86Y 的正电子放射性药物：放射化学与生物学应用。
Med Chem. 2011 Sep;7(5):380-8. doi: 10.2174/157340611796799249.